Menu
Logo

BHS Guidelines

Consult the front-line and subsequent line treatment algorithms for CLL, MCL and WM developed by the Belgian Hematology Society Lymphoproliferative Working Party below.[1]
Based on new reimbursements and robust clinical data, the existing recommendations for CLL were updated in February 2020. Download the full overview of the recently published BHS Guidelines for SLL/CLL in pdf here[1]:

Diagnostic and/or pre-treatment work-up CLL [1]
Diagnostic and/or pre-treatment work-up CLL1
Front-Line CLL [1]
Front-Line CLL1

CLL: chronic lymphocytic leukemia; 17p del/p53 mut: 17p deletion/p53 mutation; unfit for FCR: Cr Cl <70 ml/min, CIRS >6, therapy-related cytopenia, history of autoimmune cytopenia; FCR: fludarabine, cyclophosphamide, rituximab; BR: bendamustine, rituximab; Ob: obinutuzumab; Chl: chlorambucil; R: rituximab ; allo-SCT: allogeneic stem cell transplantation

Relapsed/Refractory CLL [1]
Relapsed/Refractory CLL1

R/R: relapsed/refractory; CLL: chronic lymphocytic leukemia; 17p del/p53 mut: 17p deletion/p53 mutation; CIT: chemo-immunotherapy; R: rituximab; allo-SCT: allogeneic stem cell transplantation

Front-Line MCL[2]
Front-Line MCL2

MCL: mantle cell lymphoma; CIT: chemo-immunotherapy; IF RT: •involved field radiotherapy; Auto-SCT: autologous stem cell transplantation; R: rituximab; R-CHOP: rituximab-cyclophosphamide-adriamycine-vincristin-corticosteroids; R-DHAP:rituximab-cisplatinum-cytarabine-dexamethasone; BR: bendamustine-rituximab; VR-CAP: bortezomib-rituximab-cyclophosphamide-adriamycine-corticosteroids; HD CT: high dose chemotherapy

Relapsed/Refractory MCL[2]
Relapsed/Refractory MCL2

R/R MCL: relapsed/refractory mantle cell lymphoma; allo-SCT: allogeneic stem cell transplantation; CIT: chemo-immunotherapy; R: rituximab; R-DHAP:rituximab-cisplatinum-cytarabine-dexamethasone; BR: bendamustine-rituximab; HD ARA-C: high dose cytarabine

Front-Line WM[2]
Front-Line WM2

WM: Waldenström macroglobulinemia; CIT: chemo-immunotherapy; Auto-SCT: autologous stem cell transplantation; AIC: auto-immune cytopenia; PNP: polyneuropathy; R: rituximab; R-CP: rituximab- cyclophosphamide -prednisolone; R-CD: rituximab- cyclophosphamide-dexamethasone; BR: bendamustine- rituximab; BRD: bortezomib- rituximab-dexamethasone; R-Chl: rituximab-chlorambucil

Relapsed/Refractory WM[2]
Relapsed/Refractory WM2

R/R WM: relapsed/refractory Waldenström macroglobulinemia; CIT: chemo-immunotherapy; Auto-SCT: autologous stem cell transplantation; Allo-SCT: allogeneic stem cell transplantation

Reimbursement criteria Imbruvica
Find out here which patients can benefit from ibrutinib.[3]

Practical guide

Download the practical guide with reimbursement criteria and other practicalties on Imbruvica.